Comment on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply

European Heart Journal - Cardiovascular Pharmacotherapy

2 April 2020
Organised by: Logo
ESC Journals

Contributors

Naja Emborg Vinding
Naja Emborg Vinding

Author

Rigshospitalet - Copenhagen University Hospital Copenhagen , Denmark

ESC 365 is supported by